These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11488260)

  • 1. [Apropos of atypical melancholia with Sustiva (efavirenz)].
    Lang JP; Halleguen O; Picard A; Lang JM; Danion JM
    Encephale; 2001; 27(3):290-3. PubMed ID: 11488260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
    AIDS Alert; 1998 Nov; 13(11):121-4. PubMed ID: 11365967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz: enhancing the gold standard.
    Arribas JR
    Int J STD AIDS; 2003 Oct; 14 Suppl 1():6-14. PubMed ID: 14617398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz: new preparation. An alternative to HIV protease inhibitors.
    Prescrire Int; 2000 Apr; 9(46):46-9. PubMed ID: 11503786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
    Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
    Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alpha-interferon and mental disorders].
    Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
    Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-ranging studies.
    Manion D
    Int J Clin Pract Suppl; 1999 Jun; 103():8-9. PubMed ID: 10622036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099.
    Journot V; Chene G; De Castro N; Rancinan C; Cassuto JP; Allard C; Vildé JL; Sobel A; Garré M; Molina JM;
    Clin Infect Dis; 2006 Jun; 42(12):1790-9. PubMed ID: 16705588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recreational substance use and tolerance of efavirenz in HIV-1 infected patients.
    Faggian F; Lattuada E; Lanzafame M; Antolini D; Concia E; Vento S
    AIDS Care; 2005 Oct; 17(7):908-10. PubMed ID: 16120507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.
    Allavena C; Le Moal G; Michau C; Chiffoleau A; Raffi F
    Antivir Ther; 2006; 11(2):263-5. PubMed ID: 16640107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can efavirenz be taken in the morning?
    Skeie L; Maeland A
    Scand J Infect Dis; 2006; 38(11-12):1089-91. PubMed ID: 17148083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
    J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA approves Sustiva (efavirenz) capsules, first once-daily anti-HIV drug. Food and Drug Administration.
    Res Initiat Treat Action; 1998 Oct; 4(6):13-4. PubMed ID: 11365915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():37-8. PubMed ID: 11373775
    [No Abstract]   [Full Text] [Related]  

  • 17. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination.
    James JS
    AIDS Treat News; 1998 Jul; (No 299):1-3. PubMed ID: 11365599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.